Abstract Number: 134 • 2023 Pediatric Rheumatology Symposium
Patient-Provider Communication in Pediatric Rheumatology
Background/Purpose: Communication is an essential part of medical care, especially in Pediatric Rheumatology where children have varying complex chronic diseases. However, there is paucity of…Abstract Number: 135 • 2023 Pediatric Rheumatology Symposium
Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative
Background/Purpose: Suboptimal medication adherence is a widespread problem in JIA. There are several unique features to medication adherence in JIA, including that the medications used…Abstract Number: 105 • 2023 Pediatric Rheumatology Symposium
Awareness of Multisystem Inflammatory Syndrome in Children Among U.S. Parents: A Cross-Sectional Survey
Background/Purpose: Little is known about parental awareness of multisystem inflammatory syndrome in children (MIS-C), a rare but severe sequela of SARS-CoV-2 infection. We sought to…Abstract Number: 118 • 2023 Pediatric Rheumatology Symposium
Serum Hepatocyte Growth Factor in Children with Juvenile Idiopathic Arthritis
Background/Purpose: Only limited data are available on the risk of liver fibrosis in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) on long-term…Abstract Number: 091 • 2023 Pediatric Rheumatology Symposium
Achieving Remission in Childhood-onset Systemic Lupus Erythematosus: Rapid Implementation of an EMR-integrated Dashboard to Measure Disease Activity and Remission Rates
Background/Purpose: Children with childhood-onset systemic lupus erythematosus (cSLE) experience more severe disease than their adult counterparts, in addition to high rates of clinical depressive symptoms…Abstract Number: 053 • 2023 Pediatric Rheumatology Symposium
Can Children with Colchicine Resistant FMF Be Treated with on Demand Canakinumab Regimen?– a Multicenter Study
Background/Purpose: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Without therapy, it may lead to the development of secondary amyloidosis. Treatment with colchicine…Abstract Number: 136 • 2023 Pediatric Rheumatology Symposium
Incidence and Disease Burden of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis After Non-Pharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea
Background/Purpose: Several countries have implemented non-pharmaceutical interventions (NPIs) against the coronavirus disease 2019 (COVID-19) pandemic. We investigated the impact of NPIs on the incidence of…Abstract Number: 130 • 2023 Pediatric Rheumatology Symposium
Levels of Neutrophil Extracellular Traps Correlate with Disease Activity in Pediatric Lupus
Background/Purpose: Pediatric lupus (pSLE) is a multisystemic autoimmune disease characterized by autoantibody production leading to organ damage. Neutrophil extracellular traps (NETs) are considered a potential…Abstract Number: 133 • 2023 Pediatric Rheumatology Symposium
An Interdisciplinary Team Approach to Implementation of a Social Determinants of Health Screener for Pediatric Rheumatology Patients
Background/Purpose: Adolescents with chronic disease often struggle with the transition from pediatric to adult healthcare leading to poor follow-up and negative health outcomes. Social determinants…Abstract Number: 129 • 2023 Pediatric Rheumatology Symposium
Interrogation of STAT3 Activation in Patients with Polyarticular Juvenile Arthritis (polyJIA)
Background/Purpose: A better understanding of the pathogenesis of polyJIA is necessary to guide more effective clinical care, such as the development of data-driven approaches to…Abstract Number: 039 • 2023 Pediatric Rheumatology Symposium
Towards the Definition of Cutoff Values for Disease Activity States in Systemic JIA Using the Systemic Juvenile Arthritis Disease Activity Score
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) accounts up to 15% of all patients with JIA and is distinctfrom the other disease categories due to the…Abstract Number: 054 • 2023 Pediatric Rheumatology Symposium
Craniofacial Localized Scleroderma: A Single Center Retrospective Cohort
Background/Purpose: Craniofacial localized scleroderma (LS) can lead to disfigurement and severe extracutaneous manifestations (ECMs). There is an ongoing need to standardize multidisciplinary evaluation and care.…Abstract Number: 040 • 2023 Pediatric Rheumatology Symposium
HLA DRB1*15 and Eosinophilia Are Common Among Patients with Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Over the last two decades, some children with systemic juvenile idiopathic arthritis (SJIA) have developed a severe form of interstitial lung disease (ILD) termed…Abstract Number: 043 • 2023 Pediatric Rheumatology Symposium
Development and Usability Testing of Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO)
Background/Purpose: The ChRonic nonbacterial Osteomyelitis Magnetic Resonance Imaging Scoring (CROMRIS) tool was developed to assess specific characteristics of bone and soft tissue inflammation in MRI…Abstract Number: 041 • 2023 Pediatric Rheumatology Symposium
Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort
Background/Purpose: The PedAnam (Pediatric Automated Neuropsychological Assessment Metrics) is an automatic software to evaluate cognitive performance that has recently been validated into Portugues (Brazil). The…
- « Previous Page
- 1
- …
- 544
- 545
- 546
- 547
- 548
- …
- 2607
- Next Page »
